메뉴 건너뛰기




Volumn 33, Issue 8, 2011, Pages 1023-1042

Pitavastatin calcium: Clinical review of a new antihyperlipidemic medication

Author keywords

Cholesterol; HMG CoA reductase inhibitors; Livalo; Low density lipoprotein; Pitavastatin; Statins

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; CYTOCHROME P450 3A; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; MEVACO; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

EID: 80051659998     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.07.011     Document Type: Review
Times cited : (16)

References (60)
  • 1
    • 70350180854 scopus 로고    scopus 로고
    • Top 200 drugs of 2008
    • Lamb E. Top 200 drugs of 2008. Pharmacy Times 2009.
    • (2009) Pharmacy Times
    • Lamb, E.1
  • 2
    • 84857107205 scopus 로고    scopus 로고
    • Accessed April 5, 2010
    • Pfizer 2009 Annual Report Accessed April 5, 2010. http://media.pfizer.com/files/annualreport/2009/financial/financial2009.pdf.
    • Pfizer 2009 Annual Report
  • 3
    • 0035897696 scopus 로고    scopus 로고
    • Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
    • Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults
    • Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults.
    • (2001) JAMA , vol.285 , pp. 2486-2497
  • 4
  • 5
    • 33748042671 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions
    • Shitara Y., Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006, 112:71-105.
    • (2006) Pharmacol Ther , vol.112 , pp. 71-105
    • Shitara, Y.1    Sugiyama, Y.2
  • 6
    • 0012908222 scopus 로고    scopus 로고
    • Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
    • Aoki T., Nishimura H., Nakagawa S., et al. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneimittelforschung 1997, 47:904-909.
    • (1997) Arzneimittelforschung , vol.47 , pp. 904-909
    • Aoki, T.1    Nishimura, H.2    Nakagawa, S.3
  • 7
    • 0034570787 scopus 로고    scopus 로고
    • Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells
    • Morikawa S., Umetani M., Nakagawa S., et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb 2000, 7:138-144.
    • (2000) J Atheroscler Thromb , vol.7 , pp. 138-144
    • Morikawa, S.1    Umetani, M.2    Nakagawa, S.3
  • 8
    • 9144234810 scopus 로고    scopus 로고
    • Pitavastatin, a potent hydroxymethylglutaryl coenzyme a reductase inhibitor, increases cholesterol 7 alpha-hydroxylase gene expression in HepG2 cells
    • Fan P., Zhang B., Kuroki S., Saku K. Pitavastatin, a potent hydroxymethylglutaryl coenzyme a reductase inhibitor, increases cholesterol 7 alpha-hydroxylase gene expression in HepG2 cells. Circ J 2004, 68:1061-1066.
    • (2004) Circ J , vol.68 , pp. 1061-1066
    • Fan, P.1    Zhang, B.2    Kuroki, S.3    Saku, K.4
  • 9
    • 5144220807 scopus 로고    scopus 로고
    • Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell
    • Maejima T., Yamazaki H., Aoki T., et al. Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun 2004, 324:835-839.
    • (2004) Biochem Biophys Res Commun , vol.324 , pp. 835-839
    • Maejima, T.1    Yamazaki, H.2    Aoki, T.3
  • 10
    • 26944457749 scopus 로고    scopus 로고
    • Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes
    • Saiki A., Murano T., Watanabe F., et al. Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes. J Atheroscler Thromb 2005, 12:163-168.
    • (2005) J Atheroscler Thromb , vol.12 , pp. 163-168
    • Saiki, A.1    Murano, T.2    Watanabe, F.3
  • 11
    • 0002549759 scopus 로고    scopus 로고
    • Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (4): interspecies variation in laboratory animals and humans
    • Fujino H., Kojima J., Yamada Y., Kanda H. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (4): interspecies variation in laboratory animals and humans. Drug Metab Pharmacokinetics 1999, 14:79-91.
    • (1999) Drug Metab Pharmacokinetics , vol.14 , pp. 79-91
    • Fujino, H.1    Kojima, J.2    Yamada, Y.3    Kanda, H.4
  • 12
    • 0000332988 scopus 로고    scopus 로고
    • Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (1): absorption, distribution, metabolism and excretion in rats
    • Kimata H., Fujino H., Koide H., et al. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (1): absorption, distribution, metabolism and excretion in rats. Drug Metab Pharmacokinetics 1998, 13:484-499.
    • (1998) Drug Metab Pharmacokinetics , vol.13 , pp. 484-499
    • Kimata, H.1    Fujino, H.2    Koide, H.3
  • 13
    • 0000332993 scopus 로고    scopus 로고
    • Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (2): absorption, distribution, metabolism, excretion and accumulation following repeated oral administration of 14C-NK-104 in rats
    • Fujino H., Tsunenari Y., Koide T., et al. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (2): absorption, distribution, metabolism, excretion and accumulation following repeated oral administration of 14C-NK-104 in rats. Drug Metab Pharmacokinetics 1998, 13:499-507.
    • (1998) Drug Metab Pharmacokinetics , vol.13 , pp. 499-507
    • Fujino, H.1    Tsunenari, Y.2    Koide, T.3
  • 14
    • 0001224909 scopus 로고    scopus 로고
    • Studies on metabolic fate of NK-104, a new inhibitor of HMG-CoAQ reductase (5): in vitro metabolism and plasma protein binding in animals and humans
    • Fujino H., Yamada I., Kojima J., et al. Studies on metabolic fate of NK-104, a new inhibitor of HMG-CoAQ reductase (5): in vitro metabolism and plasma protein binding in animals and humans. Xenobio Metabol Dispos 1999, 14:415-425.
    • (1999) Xenobio Metabol Dispos , vol.14 , pp. 415-425
    • Fujino, H.1    Yamada, I.2    Kojima, J.3
  • 15
    • 0032970752 scopus 로고    scopus 로고
    • Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection
    • Kojima J., Fujino H., Yosimura M., et al. Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 1999, 724:173-180.
    • (1999) J Chromatogr B Biomed Sci Appl , vol.724 , pp. 173-180
    • Kojima, J.1    Fujino, H.2    Yosimura, M.3
  • 16
    • 0032914056 scopus 로고    scopus 로고
    • Identification of metabolites of NK-104, an HMG-CoA reductase inhibitor, in rat, rabbit and dog bile
    • Kojima J., Fujino H., Abe H., et al. Identification of metabolites of NK-104, an HMG-CoA reductase inhibitor, in rat, rabbit and dog bile. Biol Pharm Bull 1999, 22:142-150.
    • (1999) Biol Pharm Bull , vol.22 , pp. 142-150
    • Kojima, J.1    Fujino, H.2    Abe, H.3
  • 17
    • 0001224909 scopus 로고    scopus 로고
    • Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (5): in vitro metabolism and plasma protein binding in animals and human
    • Fujino H., Yamada I., Kojima J., et al. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (5): in vitro metabolism and plasma protein binding in animals and human. Drug Metab Pharmacokinetics 1999, 14:415-424.
    • (1999) Drug Metab Pharmacokinetics , vol.14 , pp. 415-424
    • Fujino, H.1    Yamada, I.2    Kojima, J.3
  • 18
    • 3242695305 scopus 로고    scopus 로고
    • Effect of gemfibrozil on the metabolism of pitavastatin--determining the best animal model for human CYP and UGT activities
    • Fujino H., Saito T., Tsunenari Y., Kojima J. Effect of gemfibrozil on the metabolism of pitavastatin--determining the best animal model for human CYP and UGT activities. Drug Metabol Drug Interact 2004, 20:25-42.
    • (2004) Drug Metabol Drug Interact , vol.20 , pp. 25-42
    • Fujino, H.1    Saito, T.2    Tsunenari, Y.3    Kojima, J.4
  • 19
    • 0141997153 scopus 로고    scopus 로고
    • Effect of biliary excretion on the pharmacokinetics of pitavastatin (NK-104) in dogs
    • Kojima J., Ohshima T., Yoneda M., Sawada H. Effect of biliary excretion on the pharmacokinetics of pitavastatin (NK-104) in dogs. Drug Metab Pharmacokinetics 2001, 16:497-502.
    • (2001) Drug Metab Pharmacokinetics , vol.16 , pp. 497-502
    • Kojima, J.1    Ohshima, T.2    Yoneda, M.3    Sawada, H.4
  • 20
    • 11244283910 scopus 로고    scopus 로고
    • Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors
    • Fujino H., Saito T., Tsunenari Y., et al. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica 2004, 34:961-971.
    • (2004) Xenobiotica , vol.34 , pp. 961-971
    • Fujino, H.1    Saito, T.2    Tsunenari, Y.3
  • 21
    • 3242789321 scopus 로고    scopus 로고
    • Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase
    • Fujino H., Nakai D., Nakagomi R., et al. Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase. Arzneimittelforschung 2004, 54:382-388.
    • (2004) Arzneimittelforschung , vol.54 , pp. 382-388
    • Fujino, H.1    Nakai, D.2    Nakagomi, R.3
  • 22
    • 4644364576 scopus 로고    scopus 로고
    • Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans
    • Hirano M., Maeda K., Shitara Y., Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 2004, 311:139-146.
    • (2004) J Pharmacol Exp Ther , vol.311 , pp. 139-146
    • Hirano, M.1    Maeda, K.2    Shitara, Y.3    Sugiyama, Y.4
  • 23
    • 15244362340 scopus 로고    scopus 로고
    • Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis
    • Hui C.K., Cheung B.M., Lau G.K. Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. Br J Clin Pharmacol 2005, 59:291-297.
    • (2005) Br J Clin Pharmacol , vol.59 , pp. 291-297
    • Hui, C.K.1    Cheung, B.M.2    Lau, G.K.3
  • 24
    • 33745243715 scopus 로고    scopus 로고
    • Drug-drug interaction between pitavastatin and various drugs via OATP1B1
    • Hirano M., Maeda K., Shitara Y., Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 2006, 34:1229-1236.
    • (2006) Drug Metab Dispos , vol.34 , pp. 1229-1236
    • Hirano, M.1    Maeda, K.2    Shitara, Y.3    Sugiyama, Y.4
  • 25
    • 27444434929 scopus 로고    scopus 로고
    • Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin
    • Ando H., Tsuruoka S., Yanagihara H., et al. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol 2005, 60:494-497.
    • (2005) Br J Clin Pharmacol , vol.60 , pp. 494-497
    • Ando, H.1    Tsuruoka, S.2    Yanagihara, H.3
  • 26
    • 80051625423 scopus 로고    scopus 로고
    • Drug-drug interaction study to assess the effects of multiple-dose pitavastatin on steady-state warfarin in healthy adult volunteers
    • [Epub ahead of print] J 12
    • Inagaki Y., Hunt T., Arana B., et al. Drug-drug interaction study to assess the effects of multiple-dose pitavastatin on steady-state warfarin in healthy adult volunteers. J Clin Pharmacol 2011 January 12, [Epub ahead of print].
    • (2011) J Clin Pharmacol
    • Inagaki, Y.1    Hunt, T.2    Arana, B.3
  • 27
    • 0036231636 scopus 로고    scopus 로고
    • Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison
    • Saito Y., Yamada N., Teramoto T., et al. Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison. Arzneimittelforschung 2002, 52:251-255.
    • (2002) Arzneimittelforschung , vol.52 , pp. 251-255
    • Saito, Y.1    Yamada, N.2    Teramoto, T.3
  • 28
    • 77749345874 scopus 로고    scopus 로고
    • Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia
    • Sansanayudh N., Wongwiwatthananukit S., Putwai P., Dhumma-Upakorn R. Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia. Ann Pharmacother 2010, 44:415-423.
    • (2010) Ann Pharmacother , vol.44 , pp. 415-423
    • Sansanayudh, N.1    Wongwiwatthananukit, S.2    Putwai, P.3    Dhumma-Upakorn, R.4
  • 29
    • 67249088838 scopus 로고    scopus 로고
    • Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia
    • Budinski D., Arneson V., Hounslow N., Gratsiansky N. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin Lipidol 2009, 4:291-302.
    • (2009) Clin Lipidol , vol.4 , pp. 291-302
    • Budinski, D.1    Arneson, V.2    Hounslow, N.3    Gratsiansky, N.4
  • 30
    • 37349123865 scopus 로고    scopus 로고
    • Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia
    • Lee S.H., Chung N., Kwan J., et al. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. Clin Ther 2007, 29:2365-2373.
    • (2007) Clin Ther , vol.29 , pp. 2365-2373
    • Lee, S.H.1    Chung, N.2    Kwan, J.3
  • 31
    • 56649111325 scopus 로고    scopus 로고
    • Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study)
    • Yokote K., Bujo H., Hanaoka H., et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis 2008, 201:345-352.
    • (2008) Atherosclerosis , vol.201 , pp. 345-352
    • Yokote, K.1    Bujo, H.2    Hanaoka, H.3
  • 32
    • 47149104736 scopus 로고    scopus 로고
    • A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance
    • Sasaki J., Ikeda Y., Kuribayashi T., et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther 2008, 30:1089-1101.
    • (2008) Clin Ther , vol.30 , pp. 1089-1101
    • Sasaki, J.1    Ikeda, Y.2    Kuribayashi, T.3
  • 33
    • 69049092983 scopus 로고    scopus 로고
    • Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque. Comparison with atorvastatin
    • Toi T., Taguchi I., Yoneda S., et al. Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque. Comparison with atorvastatin. Circ J 2009, 73:1466-1472.
    • (2009) Circ J , vol.73 , pp. 1466-1472
    • Toi, T.1    Taguchi, I.2    Yoneda, S.3
  • 34
    • 39749102894 scopus 로고    scopus 로고
    • Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function
    • Sakabe K., Fukuda N., Fukuda Y., et al. Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function. Int J Cardiol 2008, 125:136-138.
    • (2008) Int J Cardiol , vol.125 , pp. 136-138
    • Sakabe, K.1    Fukuda, N.2    Fukuda, Y.3
  • 35
    • 0036234655 scopus 로고    scopus 로고
    • A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia
    • Saito Y., Yamada N., Teramoto T., et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 2002, 162:373-379.
    • (2002) Atherosclerosis , vol.162 , pp. 373-379
    • Saito, Y.1    Yamada, N.2    Teramoto, T.3
  • 36
    • 79952536047 scopus 로고    scopus 로고
    • A crossover study of rosuvastatin and pitavastatin in patients with type 2 diabetes
    • Yanagi K., Monden T., Ikeda S., et al. A crossover study of rosuvastatin and pitavastatin in patients with type 2 diabetes. Adv Ther 2011, 28:160-171.
    • (2011) Adv Ther , vol.28 , pp. 160-171
    • Yanagi, K.1    Monden, T.2    Ikeda, S.3
  • 37
    • 72549107976 scopus 로고    scopus 로고
    • Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia
    • Ose L., Budinski D., Hounslow N., Arneson V. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin 2009, 25:2755-2764.
    • (2009) Curr Med Res Opin , vol.25 , pp. 2755-2764
    • Ose, L.1    Budinski, D.2    Hounslow, N.3    Arneson, V.4
  • 38
    • 24344456373 scopus 로고    scopus 로고
    • A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia
    • Park S., Kang H.J., Rim S.J., et al. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia. Clin Ther 2005, 27:1074-1082.
    • (2005) Clin Ther , vol.27 , pp. 1074-1082
    • Park, S.1    Kang, H.J.2    Rim, S.J.3
  • 39
    • 67650095320 scopus 로고    scopus 로고
    • Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study)
    • Hiro T., Kimura T., Morimoto T., et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 2009, 54:293-302.
    • (2009) J Am Coll Cardiol , vol.54 , pp. 293-302
    • Hiro, T.1    Kimura, T.2    Morimoto, T.3
  • 41
    • 75149180515 scopus 로고    scopus 로고
    • Standards of medical care in diabetes-2010
    • American Diabetes Association
    • Standards of medical care in diabetes-2010. Diabetes Care 2010, 33(Suppl 1):S11-S61. American Diabetes Association.
    • (2010) Diabetes Care , vol.33 , Issue.SUPPL 1
  • 42
    • 77952744253 scopus 로고    scopus 로고
    • High density lipoprotein cholesterol and apolipoprotein A-I are persistently elevated during long-term treatment with pitavastatin, a new HMG-CoA reductase inhibitor
    • Fukutomi T., Takeda Y., Suzuki S., et al. High density lipoprotein cholesterol and apolipoprotein A-I are persistently elevated during long-term treatment with pitavastatin, a new HMG-CoA reductase inhibitor. Int J Cardiol 2010, 141:320-322.
    • (2010) Int J Cardiol , vol.141 , pp. 320-322
    • Fukutomi, T.1    Takeda, Y.2    Suzuki, S.3
  • 43
    • 0036015997 scopus 로고    scopus 로고
    • Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia
    • Noji Y., Higashikata T., Inazu A., et al. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2002, 163:157-164.
    • (2002) Atherosclerosis , vol.163 , pp. 157-164
    • Noji, Y.1    Higashikata, T.2    Inazu, A.3
  • 44
    • 42349116146 scopus 로고    scopus 로고
    • Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study
    • Kawashiri M.A., Nohara A., Tada H., et al. Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study. Clin Pharmacol Ther 2008, 83:731-739.
    • (2008) Clin Pharmacol Ther , vol.83 , pp. 731-739
    • Kawashiri, M.A.1    Nohara, A.2    Tada, H.3
  • 45
    • 56749106312 scopus 로고    scopus 로고
    • Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
    • Ridker P.M., Danielson E., Fonseca F.A.H., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
    • (2008) N Engl J Med , vol.359 , pp. 2195-2207
    • Ridker, P.M.1    Danielson, E.2    Fonseca, F.A.H.3
  • 46
    • 33846609195 scopus 로고    scopus 로고
    • Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis
    • Lorenz M.W., Markus H.S., Bots M.L., et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007, 115:459-467.
    • (2007) Circulation , vol.115 , pp. 459-467
    • Lorenz, M.W.1    Markus, H.S.2    Bots, M.L.3
  • 47
    • 43549105337 scopus 로고    scopus 로고
    • Impact of statin therapy on left ventricular function and carotid arterial stiffness in patients with hypercholesterolemia
    • Mizuguchi Y., Oishi Y., Miyoshi H., et al. Impact of statin therapy on left ventricular function and carotid arterial stiffness in patients with hypercholesterolemia. Circ J 2008, 72:538-544.
    • (2008) Circ J , vol.72 , pp. 538-544
    • Mizuguchi, Y.1    Oishi, Y.2    Miyoshi, H.3
  • 48
    • 58249125558 scopus 로고    scopus 로고
    • Integrated backscatter and intima-media thickness of the thoracic aorta evaluated by transesophageal echocardiography in hypercholesterolemic patients: effect of pitavastatin therapy
    • Ono K., Kawasaki M., Tanaka R., et al. Integrated backscatter and intima-media thickness of the thoracic aorta evaluated by transesophageal echocardiography in hypercholesterolemic patients: effect of pitavastatin therapy. Ultrasound Med Biol 2009, 35:193-200.
    • (2009) Ultrasound Med Biol , vol.35 , pp. 193-200
    • Ono, K.1    Kawasaki, M.2    Tanaka, R.3
  • 49
    • 42449116679 scopus 로고    scopus 로고
    • Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome
    • Nakamura T., Obata J.E., Kitta Y., et al. Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome. J Cardiovasc Pharmacol 2008, 51:365-371.
    • (2008) J Cardiovasc Pharmacol , vol.51 , pp. 365-371
    • Nakamura, T.1    Obata, J.E.2    Kitta, Y.3
  • 50
    • 33751400537 scopus 로고    scopus 로고
    • Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): rationale and design
    • Miyauchi H., Kimura T., Morimoto T., et al. Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): rationale and design. Circ J 2006, 70:1624-1628.
    • (2006) Circ J , vol.70 , pp. 1624-1628
    • Miyauchi, H.1    Kimura, T.2    Morimoto, T.3
  • 51
    • 78249268245 scopus 로고    scopus 로고
    • More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome-sub-analysis of JAPAN-ACS study
    • Arai H., Hiro T., Kimura T., et al. More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome-sub-analysis of JAPAN-ACS study. J Atheroscler Thromb 2010, 17:1096-1107.
    • (2010) J Atheroscler Thromb , vol.17 , pp. 1096-1107
    • Arai, H.1    Hiro, T.2    Kimura, T.3
  • 52
    • 11144355354 scopus 로고    scopus 로고
    • Intensive versus moderate lipid lowering with statins after acute coronary syndromes
    • Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
    • (2004) N Engl J Med , vol.350 , pp. 1495-1504
    • Cannon, C.P.1    Braunwald, E.2    McCabe, C.H.3
  • 53
    • 52949154682 scopus 로고    scopus 로고
    • A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (Livalo tablet)-Livalo Effectiveness and Safety (LIVES) Study
    • Kurihara Y., Douzono T., Kawakita K. A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (Livalo tablet)-Livalo Effectiveness and Safety (LIVES) Study. Jpn Pharmacol Ther 2008, 36:709-731.
    • (2008) Jpn Pharmacol Ther , vol.36 , pp. 709-731
    • Kurihara, Y.1    Douzono, T.2    Kawakita, K.3
  • 54
    • 77952420085 scopus 로고    scopus 로고
    • Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia
    • Ose L., Budinski D., Hounslow N., Arneson V. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis 2010, 210:202-208.
    • (2010) Atherosclerosis , vol.210 , pp. 202-208
    • Ose, L.1    Budinski, D.2    Hounslow, N.3    Arneson, V.4
  • 55
    • 33745255122 scopus 로고    scopus 로고
    • Statin use and incident nuclear cataract
    • Klein B.E.K., Klein R., Lee K.E., Grady L.M. Statin use and incident nuclear cataract. JAMA 2006, 295:2752-2758.
    • (2006) JAMA , vol.295 , pp. 2752-2758
    • Klein, B.E.K.1    Klein, R.2    Lee, K.E.3    Grady, L.M.4
  • 56
    • 34548433405 scopus 로고    scopus 로고
    • Meta-analysis of the role of statin therapy in reducing myocardial infarction following elective percutaneous coronary intervention
    • Mood G.R., Bavry A.A., Roukoz H., Bhatt D.L. Meta-analysis of the role of statin therapy in reducing myocardial infarction following elective percutaneous coronary intervention. Am J Cardiol 2007, 100:919-923.
    • (2007) Am J Cardiol , vol.100 , pp. 919-923
    • Mood, G.R.1    Bavry, A.A.2    Roukoz, H.3    Bhatt, D.L.4
  • 57
    • 34548697581 scopus 로고    scopus 로고
    • Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the aggrastat to Zocor and pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 trials)
    • Murphy S.A., Cannon C.P., Wiviott S.D., et al. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the aggrastat to Zocor and pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 trials). Am J Cardiol 2007, 100:1047-1051.
    • (2007) Am J Cardiol , vol.100 , pp. 1047-1051
    • Murphy, S.A.1    Cannon, C.P.2    Wiviott, S.D.3
  • 58
    • 27744603499 scopus 로고    scopus 로고
    • High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial
    • Pedersen T.R., Faergeman O., Kastelein J.J.P., et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005, 294:2437-2445.
    • (2005) JAMA , vol.294 , pp. 2437-2445
    • Pedersen, T.R.1    Faergeman, O.2    Kastelein, J.J.P.3
  • 59
    • 0037075262 scopus 로고    scopus 로고
    • Cerivastatin and reports of fatal rhabdomyolysis
    • Staffa J.A., Chang J., Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002, 346:539-a.
    • (2002) N Engl J Med , vol.346
    • Staffa, J.A.1    Chang, J.2    Green, L.3
  • 60
    • 80051615248 scopus 로고    scopus 로고
    • Rationale and design of a study to evaluate effects of pitavastatin on Japanese patients with chronic heart failure: the pitavastatin heart failure study (PEARL study)
    • [Epub ahead of print] N 12
    • Mizuma H., Inoue T., Takano H., et al. Rationale and design of a study to evaluate effects of pitavastatin on Japanese patients with chronic heart failure: the pitavastatin heart failure study (PEARL study). Int J Cardiol 2010 November 12, [Epub ahead of print].
    • (2010) Int J Cardiol
    • Mizuma, H.1    Inoue, T.2    Takano, H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.